First filing for Kowa's peretinoin, for recurrent liver cancer
This article was originally published in Scrip
Kowa has filed an application in Japan for the approval of peretinoin (NIK-333) for the suppression of recurrence of previously treated hepatocellular carcinoma (HCC) in hepatitis C patients.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.